Literature DB >> 21279532

Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP).

Y X Liew1, M P Chlebicki, W Lee, L Y Hsu, A L Kwa.   

Abstract

Clinicians have used procalcitonin (PCT) (biomarker to differentiate bacterial from non-bacterial sepsis) to guide use of antibiotics in patients. As the data for utility of PCT to discontinue antibiotics in an antimicrobial stewardship program (ASP) are lacking, we aim to describe the outcomes of patients in whom PCT was used to discontinue antibiotics under our ASP. An antimicrobial stewardship (AS) team intervened to discontinue antibiotics in patients with persistent fever or leucocytosis, source of sepsis unknown or negative bacteriological cultures, who had completed an adequate course of antibiotic therapy and had a PCT of <0.5 μg/L. Main outcomes evaluated were 14-day re-infection, 30-day mortality and readmission. Antibiotic therapy was discontinued in 42 patients in 1 year. Unknown source of sepsis was found in 38% of the patients (including possible malignant fever) and culture-negative pneumonia was found in 21%. Two patients died of advanced cancer. One patient decided for comfort care and died one week later. One patient died due to a second episode of pneumonia 37 days after first PCT test. Six patients were readmitted within 30 days due to non-infectious causes. Three patients were readmitted due to culture-negative pneumonia. None had a 14-day re-infection. PCT used to discontinue antibiotics under our ASP did not compromise patients' outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21279532     DOI: 10.1007/s10096-011-1165-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Authors:  Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

2.  A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria.

Authors:  Thomas G Slama; Alpesh Amin; Stephen A Brunton; Thomas M File; Gary Milkovich; Keith A Rodvold; Daniel F Sahm; Joseph Varon; David Weiland
Journal:  Am J Med       Date:  2005-07       Impact factor: 4.965

3.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.

Authors:  Mirjam Christ-Crain; Daiana Stolz; Roland Bingisser; Christian Müller; David Miedinger; Peter R Huber; Werner Zimmerli; Stephan Harbarth; Michael Tamm; Beat Müller
Journal:  Am J Respir Crit Care Med       Date:  2006-04-07       Impact factor: 21.405

Review 4.  Community factors in the development of antibiotic resistance.

Authors:  Elaine Larson
Journal:  Annu Rev Public Health       Date:  2007       Impact factor: 21.981

5.  Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy.

Authors:  Daiana Stolz; Mirjam Christ-Crain; Roland Bingisser; Jörg Leuppi; David Miedinger; Christian Müller; Peter Huber; Beat Müller; Michael Tamm
Journal:  Chest       Date:  2007-01       Impact factor: 9.410

6.  Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.

Authors:  S Harbarth; K Holeckova; C Froidevaux; D Pittet; B Ricou; G E Grau; L Vadas; J Pugin
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

7.  Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC).

Authors:  Lynne Sehulster; Raymond Y W Chinn
Journal:  MMWR Recomm Rep       Date:  2003-06-06

8.  Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care.

Authors:  Matthias Briel; Philipp Schuetz; Beat Mueller; Jim Young; Ursula Schild; Charly Nusbaumer; Pierre Périat; Heiner C Bucher; Mirjam Christ-Crain
Journal:  Arch Intern Med       Date:  2008-10-13

9.  Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial.

Authors:  Lila Bouadma; Charles-Edouard Luyt; Florence Tubach; Christophe Cracco; Antonio Alvarez; Carole Schwebel; Frédérique Schortgen; Sigismond Lasocki; Benoît Veber; Monique Dehoux; Maguy Bernard; Blandine Pasquet; Bernard Régnier; Christian Brun-Buisson; Jean Chastre; Michel Wolff
Journal:  Lancet       Date:  2010-01-25       Impact factor: 79.321

10.  Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.

Authors:  Vandack Nobre; Stephan Harbarth; Jean-Daniel Graf; Peter Rohner; Jérôme Pugin
Journal:  Am J Respir Crit Care Med       Date:  2007-12-20       Impact factor: 21.405

View more
  6 in total

1.  Utility and safety of procalcitonin in an antimicrobial stewardship program (ASP) in patients with malignancies.

Authors:  Y X Liew; W Lee; Y Y Cai; J Teo; S S-L Tang; R W-Q Ong; C L-L Lim; P B Lingegowda; A L-H Kwa; M P Chlebicki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-08       Impact factor: 3.267

2.  A Qualitative Analysis of Implementation of Antimicrobial Stewardship at 3 Academic Hospitals: Understanding the Key Influences on Success.

Authors:  Lianne Jeffs; Nisha Thampi; Maria Maione; Marilyn Steinberg; Andrew M Morris; Chaim M Bell
Journal:  Can J Hosp Pharm       Date:  2015 Sep-Oct

3.  Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

Authors:  K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern
Journal:  Infection       Date:  2016-06       Impact factor: 3.553

4.  [Association of inflammatory indices with the severity of urinary sepsis: analysis of 70 cases].

Authors:  Leming Tan; Cheng Yang; Xukai Yang; Yangmin Wang; Gaoping Cai; Zhigang Cao; Chuang Huang; Dongbo Xu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-01-30

Review 5.  Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy.

Authors:  Ashitha L Vijayan; Shilpa Ravindran; R Saikant; S Lakshmi; R Kartik; Manoj G
Journal:  J Intensive Care       Date:  2017-08-03

6.  Utility and Applicability of Rapid Diagnostic Testing in Antimicrobial Stewardship in the Asia-Pacific Region: A Delphi Consensus.

Authors:  Anucha Apisarnthanarak; Hong Bin Kim; Luke S P Moore; Yonghong Xiao; Sanjeev Singh; Yohei Doi; Andrea Lay-Hoon Kwa; Sasheela Sri La Sri Ponnampalavanar; Qing Cao; Shin-Woo Kim; Hyukmin Lee; Pitak Santanirand
Journal:  Clin Infect Dis       Date:  2022-06-10       Impact factor: 20.999

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.